Overview
The implementation of the HTA regulation is well underway and all stakeholders are actively preparing for the application of the Regulation and the future EU HTA system, starting in January 2025. European methodologies and process proposals have been developed and are now up for review by the HTA Coordination Group and its recently established sub-groups. In parallel, the European Commission, Member States’ HTA Agencies, the European Medicines Agency, Industry, Patients and Clinicians’ organisations and all stakeholders are delivering aligned with their respective action plans and the activities that remain to be accomplished in the year to come.
This Forum provides a neutral platform for the various stakeholders to discuss the several aspects that should be put into practice to create a successful European system that goes beyond the union of current national practices but focuses on joint work and accomplishes the primary goal of the HTA Regulation – contributing to faster patient access.
Goals of the Forum:
- Discuss various strategic elements related to the implementation of the HTA Regulation from the European Commission, EMA, HTA Coordination Group, Industry, Member States’, Patients’ and Clinicians’ perspectives.
- Provide an opportunity to ask the burning questions that will inform internal company’s preparedness and discussions, such as inter-department preparedness (e.g. HTA, regulatory and clinical development) or future methodologies and processes for the joint clinical assessment (JCA).
- Assist in navigating the on-going policy discussions.
- Give insights into the work of Heads of HTA Agencies and European Commission’s Member State Coordination Group on HTA, and their expected activities for 2024.
Free Webinar: Essentials on Health Technology Assessment (HTA) and the EU Regulation (HTAR)
“Accompanying the HTA Forum, this webinar goes through the key steps of the HTA process and provides you with the knowledge foundation of the EU HTA Regulation and its implications for national authorities and stakeholders. Watch the complimentary webinar, now available online.”
Program Committee
-
Ansgar Hebborn, PhD, MBA Head - Access Policy Affairs Europe
F. Hoffmann-La Roche AG, Switzerland -
Claudine Sapède, PharmD Director, Global HTA Policy
NOVARTIS INTERNATIONAL, Switzerland -
Inka Heikkinen, MBA, MSc Regulatory Policy Lead
Lundbeck, Denmark -
Lara Wolfson AVP & Head, HTA Statistics
MSD Switzerland, Switzerland -
Matias Olsen, MA Senior Manager, Public Affairs & Policy
European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Belgium -
Maya Matthews Head of Unit State of Health, European Semester, Health Technology Assessment
European Commission , Belgium -
Michael Berntgen, PhD Head of Scientific Evidence Generation
European Medicines Agency, Netherlands -
Niklas Hedberg, MPharm HTACG Co-Chair & Chief Pharmacist
Dental and Pharmaceutical Benefits Agency, TLV, Sweden -
Rui Santos Ivo President, Executive Board
INFARMED - National Authority of Medicines and Health Products, Portugal -
Valentina Barbuto Policy Officer
European Commission, Belgium -
Valentina Strammiello, MA Director of Programmes
European Patients' Forum, Belgium -
Sara Torgal, MPharm Senior Manager, Scientific Programs
DIA, Switzerland -
Ramiro Gilardino Global HTA & Access Policy Lead
MSD Switzerland, Switzerland
Have an account?